Company

Neuren Pharmaceuticals Ltd

ASX:NEU

Neuren Pharmaceuticals Ltd (ASX:NEU) is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood.

32 stories · page 2 of 2

Pharma & Biotech

Neuren Pharmaceuticals progresses Phase 2 trials for brain treatment drug

By Proactive 28/01/2014

Pharma & Biotech

Neuren Pharmaceuticals' shares trade heavy volume

By Proactive 22/11/2013

Pharma & Biotech

Neuren Pharmaceuticals raises $21.5M to commercialise brain treatment drugs

By Proactive 22/10/2013

Pharma & Biotech

Neuren Pharmaceuticals launches capital raising

By Proactive 18/10/2013

Pharma & Biotech

Neuren Pharmaceuticals gets nod from FDA to trial new drug for Autism

By Proactive 09/09/2013

Pharma & Biotech

Neuren Pharmaceuticals cranks up the volume with 11 million shares traded

By Proactive 14/08/2013

Pharma & Biotech

Neuren Pharmaceuticals in pre-open to address market chatter

By Proactive 05/08/2013

Pharma & Biotech

Neuren Pharmaceuticals receives notice of allowance by USPTO for neuropathy patents

By Proactive 12/07/2013

Pharma & Biotech

Neuren Pharmaceuticals given US approval for clinical trial of Rett Syndrome drug

By Proactive 24/12/2012

Pharma & Biotech

Neuren Pharmaceuticals’ 53% share price jump prompts ASX query

By Proactive 25/10/2012

Pharma & Biotech

Neuren Pharmaceuticals gains grant for Phase 2 trials of Neuren Rett Syndrome treatment

By Proactive 06/07/2012

Pharma & Biotech

Neuren Pharmaceuticals to begin testing antibodies used for cancer treatment

By Proactive 19/05/2011